A Study of E6011 in Japanese Subjects With Rheumatoid Arthritis

NCT02196558 | Completed Phase 1 Results

• 1 other identifier: E6011-J081-103
• Study Type: interventional
• Target: 53
• Locations: 1 country
• Sites: 12

Brief Summary

This study consist of treatment phase (12 weeks) and extension phase (40 weeks). This study is a multicenter, open-label, uncontrolled, multiple ascending dose (MAD) study to evaluate mainly the safety and tolerability of 12-week repeated subcutaneous administration of E6011 in Japanese subjects with Rheumatoid Arthritis. First 12 subjects will enroll as 100 mg group, next 12 subjects will enroll as 200 mg group, and last 9 subjects will enroll as 400 mg group. A total of 33 subjects will receive repeated subcutaneous administration of E6011. Subjects who roll over onto the Extension phase will have continued monitoring until 52 weeks after the initial administration.

Conditions

Arthritis, Rheumatoid

Keywords

Rheumatoid Arthritis; Japanese subjects

Outcome Measures

Primary Outcomes (1)

• Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

  Up to 52 Weeks

Secondary Outcomes (2)

• Number of Participants With Positive Anti-E6011 Antibodies Results

  Up to 52 weeks

• Serum Concentrations of E6011

  At Week 0 (predose), Week 1, 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 (postdose)

Study Arms (3)

E6011, 100 mg Arm

EXPERIMENTAL

E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase).100 mg group will receive E6011 subcutaneously, 1 ml. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).

Drug: E6011

E6011, 200 mg Arm

EXPERIMENTAL

E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase). 200 mg group will receive E6011 subcutaneously, 1 ml each at two sites. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).

Drug: E6011

E6011, 400 mg Arm

EXPERIMENTAL

E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks up to 10 weeks (treatment phase). 400 mg group will receive E6011 subcutaneously, 1 ml each at four sites or 2 ml each at two sites. If a subject intends to continue administrations, the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension Phase).

Drug: E6011

Interventions

E6011 DRUG

E6011, 100 mg Arm; E6011, 200 mg Arm; E6011, 400 mg Arm

Eligibility Criteria

• Age: 20 Years - 64 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Subjects must meet all of the following criteria to be included in this study:
• Japanese patients aged 20 to 64 years old at the time of informed consent.
• Diagnosed with rheumatoid arthritis (RA) who meet the 1987 ACR or 2010 ACR/EULAR criteria.
• Presenting tenderness in more than 4 joints (out of 68) and swelling in more than 4 joints (out of 66) at Screening and Observation phase.
• Never been treated with non-anti-TNF biologics or never been treated with 2 or more anti-TNF agents.
• Subjects with greater than or equal to 0.6 mg/dL of high-sensitivity CRP (hs-CRP) level or greater than or equal to 28 mm/hr of erythrocyte sedimentation rate (ESR) at Screening.
• Weighs greater than or equal to 30 kg and less than or equal to 100 kg at Screening.
• Consent to use contraception (both the subject and the subject's partner), for at least 70 days after the last dose of study medication starting on the day of informed consent, if the subject is a man capable of reproduction or a woman of childbearing potential.
• Has voluntarily consented, in writing, to participate in this study
• Has been thoroughly briefed on the conditions for participation in the study, and is willing and able to comply with all aspects of the protocol.

You may not qualify if:

• Subjects who meet any of the following criteria will be excluded from this study:
• Any history or complication of inflammatory arthritic disorder other than rheumatoid arthritis or Sjogren's syndrome.
• Meet Class 4 with the Steinbrocker functional classification.
• History or current clinical condition, or associated complications of malignant tumor, lymphoma, leukemia, or lymphoproliferative disease.
• Immunodeficiency or history of HIV infection
• Infection requiring hospitalization or intravenous administration of antibiotics within 4 weeks before the first dose of study treatment, or an infection requiring oral antibiotics within 2 weeks before the first dose of study treatment.
• History of tuberculosis or current complication of active tuberculosis.
• History of severe allergy (shock, or anaphylactoid symptoms).
• History of clinically important vascular edema, hematemesis, hemorrhagic stool, or hemoptysis.
• History of acute myocardial infarction, cerebral infarction, cerebral hemorrhage, or arteriosclerosis obliterans.
• History of clinically important vasculitis (such as mononeuritis multiplex).
• Tested positive for any of the following at Screening: human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBs antigen), hepatitis B virus surface antibody (HBs antibody), hepatitis B virus core antibody (HBc antibody), hepatitis B virus DNA (HBV DNA), hepatitis C virus antibody (HCV antibody), human T-lymphotrophic virus Type I antibody (HTLV-1 antibody), or syphilis.
• Any result other than negative in tuberculosis test (T-SPOT.TB Test or QuantiFERON TB Gold Test) at Screening.
• Findings indicating a history of tuberculosis on chest X-ray at Screening.
• Ineligible to participate in the study in the opinion of the investigator or sub investigator.

Sponsors & Collaborators

• Eisai Co., Ltd.: lead

Study Sites (12)

Unknown Facility

Kitakyushu, Fukuoka, Japan

Location

Unknown Facility

Sapporo, Hokkaido, Japan

Location

Unknown Facility

Kakogawa, Hyōgo, Japan

Location

Unknown Facility

Katō, Hyōgo, Japan

Location

Unknown Facility

Kahoku-gun, Ishikawa-ken, Japan

Location

Unknown Facility

Yokohama, Kanagawa, Japan

Location

Unknown Facility

Hamamatsu, Shizuoka, Japan

Location

Unknown Facility

Chuo-Ku, Tokyo, Japan

Location

Unknown Facility

Meguro-Ku, Tokyo, Japan

Location

Unknown Facility

Ōta-ku, Tokyo, Japan

Location

Unknown Facility

Shinjuku-Ku, Tokyo, Japan

Location

Unknown Facility

Miyazaki, Japan

Location

Related Publications (1)

• Tanaka Y, Takeuchi T, Umehara H, Nanki T, Yasuda N, Tago F, Kawakubo M, Kitahara Y, Hojo S, Kawano T, Imai T. Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. Mod Rheumatol. 2018 Jan;28(1):58-65. doi: 10.1080/14397595.2017.1337056. Epub 2017 Jul 6.

  PMID: 28681650 DERIVED

MeSH Terms

Conditions

Arthritis, Rheumatoid

Interventions

quetmolimab

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Results Point of Contact

• Title: Inquiry Service.
• Organization: Eisai Co., Ltd.

eisai-chiken_hotline@hhc.eisai.co.jp

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 16, 2014
• First Posted: July 22, 2014
• Study Start: May 26, 2014
• Primary Completion: August 12, 2016
• Study Completion: July 13, 2017
• Last Updated: August 13, 2020
• Results First Posted: August 13, 2020

Record last verified: 2017-08

Locations

JP (12)